![]() ![]() Now, Deming has heard from investors looking for her help vetting potential investments in the space. And analysts expect one type of anti-aging therapeutic, known as senolytics, to upend a $20 billion market. ![]() Companies like Alphabet's Calico and drug giant Novartis have also taken up research on aging, while startups like Ambrosia Medical are embarking on controversial research, charging $8,000 to participate in a trial to see how blood transfusions from younger people. These days, Deming isn't alone in the space. For example, Elixir Pharmaceuticals, a company founded in the early 2000s that was backed by ARCH Ventures, ultimately shut down. ![]() The anti-aging field has seen its fair share of failures, as well. "I don't blame them, if I were in their shoes having spent the past two decades investing in cancer how would I process the idea of aging?" she said. In 2017 alone, $133 billion was spent on cancer treatments, and there were an estimated 700 companies have cancer drugs in development. For the most part, biotech investments had been flowing into cancer-focused biotechs, another area that's been exploding. "To them it was a science fiction story," Deming said. When first talking to the biotech venture capital crowd, they were skeptical. Others, like Spring Discovery, are aiming to speed up the process of discovering new aging therapies.ĭeming, who's now 24, recalls when she first tried to fundraise for her fund after moving to the Bay Area. The six companies include one focused on hibernation and how humans could tap into animals' "superpowers" and a spin-out from a regenerative medicine lab that's focused on reversing arthritis. On Wednesday, her first class of companies graduated from her fund's Age1 accelerator, aimed at helping younger companies advance their research. This story is available exclusively to Business InsiderĪnd start reading now. Account icon An icon in the shape of a person's head and shoulders. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |